C07C275/18

Urea group containing anti-sagging rheology control agents

The present invention relates to a urea group containing product comprising one or more species of formula (I) R.sup.1—X—(C═O)—[NH—R.sup.2—NH—(C═O)—NH—R.sup.3—NH—(C═O)].sub.n—NH—R.sup.2—NH—(C═O)—X—R.sup.1 (I), 5 wherein R.sup.1 is independently selected from organic groups having (4) to (200) carbon atoms, X is O or NR.sup.4, wherein R.sup.4 is a hydrogen atom or an aliphatic or aromatic group having (1) to (30) carbon atoms, R.sup.2 is independently selected from hydrocarbyl groups having (4) to (40) carbon atoms, R.sup.3 is independently selected from hydrocarbyl groups having (2) to (40) carbon atoms, and wherein on average (76) to (100) mol % of all R.sup.3 groups contained in the one or more species of formula (I) are hydrocarbyl groups having (2) or (3) carbon atoms, and n is an integer of (2) to (150). The invention further relates to a method of manufacturing such urea group containing products, liquid compositions containing the same and the use of such liquid compositions as rheology control additives. Furthermore, the invention relates to a process for rheology adjustment adding such liquid composition to semi-finished or final products. The invention also relates to an article coated with the liquid composition.

Urea group containing anti-sagging rheology control agents

The present invention relates to a urea group containing product comprising one or more species of formula (I) R.sup.1—X—(C═O)—[NH—R.sup.2—NH—(C═O)—NH—R.sup.3—NH—(C═O)].sub.n—NH—R.sup.2—NH—(C═O)—X—R.sup.1 (I), 5 wherein R.sup.1 is independently selected from organic groups having (4) to (200) carbon atoms, X is O or NR.sup.4, wherein R.sup.4 is a hydrogen atom or an aliphatic or aromatic group having (1) to (30) carbon atoms, R.sup.2 is independently selected from hydrocarbyl groups having (4) to (40) carbon atoms, R.sup.3 is independently selected from hydrocarbyl groups having (2) to (40) carbon atoms, and wherein on average (76) to (100) mol % of all R.sup.3 groups contained in the one or more species of formula (I) are hydrocarbyl groups having (2) or (3) carbon atoms, and n is an integer of (2) to (150). The invention further relates to a method of manufacturing such urea group containing products, liquid compositions containing the same and the use of such liquid compositions as rheology control additives. Furthermore, the invention relates to a process for rheology adjustment adding such liquid composition to semi-finished or final products. The invention also relates to an article coated with the liquid composition.

UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR

The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.

Carbamides for separating uranium(VI) and plutonium(IV) without reducing the plutonium(IV)

The use of carbamides as extractants for fully or partially separating uranium(VI) from plutonium(IV) in an aqueous solution obtained by dissolving a spent nuclear fuel in nitric acid, by method of liquid-liquid extraction, without carrying out any reduction of the plutonium(IV) to plutonium(III). The invention also relates to new carbamides. Uses are the processing of spent nuclear fuels based on uranium (especially uranium oxides—UOX) or uranium and plutonium (especially mixed uranium and plutonium oxides—MOX).

FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES

Fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, compounds, compositions and methods are to provide nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Method for producing carbamate and method for producing isocyanate

The present invention provides a method for producing a carbamate that includes a step (1) and a step (2) described below: (1) a step of producing a compound (A) having a urea linkage, using an organic primary amine having at least one primary amino group per molecule and at least one compound selected from among carbon dioxide and carbonic acid derivatives, at a temperature lower than the thermal dissociation temperature of the urea linkage; and (2) a step of reacting the compound (A) with a carbonate ester to produce a carbamate.

Method for producing carbamate and method for producing isocyanate

The present invention provides a method for producing a carbamate that includes a step (1) and a step (2) described below: (1) a step of producing a compound (A) having a urea linkage, using an organic primary amine having at least one primary amino group per molecule and at least one compound selected from among carbon dioxide and carbonic acid derivatives, at a temperature lower than the thermal dissociation temperature of the urea linkage; and (2) a step of reacting the compound (A) with a carbonate ester to produce a carbamate.

CARBAMIDES FOR SEPARATING URANIUM(VI) AND PLUTONIUM(IV) WITHOUT REDUCING THE PLUTONIUM(IV)

The-use of carbamides as extractants for fully or partially separating uranium(VI) from plutonium(IV) in an aqueous solution obtained by dissolving a spent nuclear fuel in nitric acid, by method of liquid-liquid extraction, without carrying out any reduction of the plutonium(IV) to plutonium(III). The invention also relates to new carbamides. Uses are the processing of spent nuclear fuels based on uranium (especially uranium oxides—UOX) or uranium and plutonium (especially mixed uranium and plutonium oxides—MOX).

CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF
20220401401 · 2022-12-22 ·

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

NAMPT MODULATORS

Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

##STR00001##